RecruitingRecruiting
Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1
NCT06353321 · University of Texas Southwestern Medical Center
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on the RefleXion X1 System in Patients Already Undergoing Diagnostic PET (Positron Emission Tomography) PSMA (Prostate Specific Membrane Antigen) Imaging
About this study
In this non-significant risk (NSR) study, investigators will perform imaging only (no treatment) on the X1 platform immediately following an already planned PET/CT diagnostic imaging using Illuccix for standard of care indications in men with prostate cancer of various stages. This approach will be used to assess imaging performance of the X1 in comparison to diagnostic imaging scanners. Evidence from this study will supplement and enhance technical understanding of the PSMA-11-guided BgRT delivery in the setting of prostate cancer. As such, the patient population selected for this investigation is meant to optimally represent the spectrum of cases, with respect to motion and radiographic environment that a radiation oncologist may encounter in practice.
Eligibility criteria
Inclusion Criteria:
* Men with prostate adenocarcinoma undergoing standard of care PSMA-PET imaging for initial staging or re-staging at suspected relapse/progression
Exclusion Criteria:
* 1\. Known psychiatric or substance abuse disorder which in the opinion of the investigator would interfere with study conduct
2\. Patient weight exceeding 450 lb (weight limit of RefleXion X1 system)
3\. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements.
Study design
Enrollment target: 25 participants
Age groups: child, adult, older_adult
Timeline
Starts: 2024-12-12
Estimated completion: 2026-12-14
Last updated: 2026-01-12
Interventions
Diagnostic Test: PET-CT imaging subsystem of the RefleXion X1 System Device
Primary outcomes
- • Qualitative assessment of RefleXion X1 imaging performance with Illuccix PSMA PET imaging agent immediately following a standard of care Illuccix PET/CT (From time of Reflexion scan to 48 hours after scan for adverse event evaluation)
Sponsor
University of Texas Southwestern Medical Center · other
With: RefleXion Medical
Contacts & investigators
ContactSarah Neufeld, MS, MBA · contact · Sarah.Hardee@UTSouthwestern.edu · 214 648-1836
ContactCristian Gonzalez · contact · Cristian.Gonzalez@UTSouthwestern.edu · 214 648-1836
InvestigatorNeil Desai, MD · principal_investigator, University of Texas Southwestern Medical Center
All locations (1)
Ut Southwestern Medical CenterRecruiting
Dallas, Texas, United States